STOCKHOLM, Oct. 15, 2021 /PRNewswire/ -- Medivir AB
(Nasdaq Stockholm: MVIR) today announces that a joint
patent application for MALT1 inhibitors submitted together with
Rheos Medicines, Inc., a US-based biopharmaceutical company, has
been made public.
The patent application is an outcome of the option agreement
that was previously entered into between the two companies
regarding Medivir's preclinical MALT1 project. Neither target nor
partner has previously been disclosed. Under the option agreement,
Rheos has the right to evaluate Medivir's MALT1 inhibitors in
addition to its own internal work in this field.
- "This option agreement is a good
example of how Medivir is creating value out of early internal
research programs that were terminated in connection with the
strategic shift made in 2018" says Magnus
Christensen, Interim CEO of Medivir.
For further information, please contact:
Magnus Christensen, Interim CEO,
Medivir AB,
Phone: +46 (0)73 125 0620.
magnus.christensen@medivir.com
About Medivir
Medivir develops innovative drugs with a focus on cancer where the
unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
MIV-818, a pro-drug designed to selectively treat liver cancer
cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's
business model, and the drug development is conducted either by
Medivir or in partnership. Birinapant, a SMAC mimetic, is
exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be
developed in combination with IGM-antibodies for the treatment of
solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq
Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/a-joint-patent-application-for-malt1-inhibitors-published,c3433851
The following files are available for download:
|
https://mb.cision.com/Main/652/3433851/1481551.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/a-joint-patent-application-for-malt1-inhibitors-published-301401216.html
SOURCE Medivir
